Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

NCT02802748 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Oral Vinorelbine
DRUG: Letrozole

Sponsor

SOLTI Breast Cancer Research Group

Collaborators

[object Object]